Also trades as: BFRIW (NASDAQ) · $vol 0M
BFRI NASDAQ
Biofrontera Inc.
1W: -14.4%
1M: -33.5%
3M: -12.9%
YTD: +39.3%
1Y: -1.0%
3Y: -88.1%
$1.01
-0.03 (-2.40%)
Weekly Expected Move ±12.9%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$13.0M
52W Range0.5547-1.66
Volume334,473
Avg Volume468,402
Beta0.84
Dividend—
Analyst Ratings
Company Info
CEOHermann Lübbert
Employees89
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2021-10-29
Websitebiofrontera-us.com
660 Main Street
Woburn, MA 01801
US
Woburn, MA 01801
US
781 245 1325
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Latest News
Biofrontera (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera outlines September 28, 2026 PDUFA date and expects sBCC launch in Q1 2027 amid ITC lamp remediation
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Luebbert Hermann | M-Exempt | 62,500 | — | 2026-07-28 |
| Luebbert Hermann | M-Exempt | 62,500 | — | 2026-07-28 |
| Leffler Eugene Frede | M-Exempt | 31,250 | — | 2026-07-28 |
| Leffler Eugene Frede | M-Exempt | 31,250 | — | 2026-07-28 |
| Luebbert Hermann | M-Exempt | 137,500 | — | 2026-03-05 |